Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors

BioDrugs 2026

View at publisher
Authors: Rujiao Liu, Hui Cheng Jing, Yang Chen, Shuiping Gao, Jinghao Zhang, Jinghao Zhang, Xubo Cao, Yuanyuan Liu, Yuanyuan Liu, Meng Meng, Cong Chen, Ci Sun
+6 more Haoyu Yu, Qingyu Wang, Jing Li, Yanmin Wu, Jian Zhang, Jian Zhang
DOI: 10.1007/s40259-025-00751-z
Cited by: 0
References: 30

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology Immunotherapy and Immune Responses

Publication details

Journal / source
BioDrugs
Volume
40
Issue
2
Pages
335–348
Publication date
15 January 2026
Language
EN